Nantes-based GenSensor, a deeptech company that optimises the development and production of biomedicines, announced that it has secured €2M in a fresh round of funding.
GenSensor seeks to advance the research, manufacture, and use of novel medicines by reindustrializing their production in France and, more widely, by becoming a vital partner for innovators in the pharmaceutical industry.
The funding came from GO Capital, Sodero Gestion and Bpifrance.
Founded in 2021, GenSensor has been developing a system for monitoring biological parameters during the manufacturing of biological pharmaceuticals, such as gene therapy vectors, vaccinations, and monoclonal antibodies.
These biomedicines offer a significant improvement in patient treatment. They currently make up 56 percent of the pharmaceutical pipeline on the planet.
According to GenSensor, despite making up just 4 percent of prescription medications, these compounds currently account for 33 percent of the pharmaceutical market’s value.
The money raised will allow GenSensor to finish the industrial development of its robot and launch the first gene therapy, vaccine, and antibody manufacturing applications.
GenSensor is a deeptech firm with a focus on biotech. The company was founded by Jean-Marie Charpin and Charles Hébert with the goal of creating online companion tools for more ethical and effective manufacture of biological pharmaceuticals.
The company hopes to provide access to biological treatments by enhancing bioproduction. It includes all test procedures from sampling to bioinformatics analysis and is the first automated online robot for real-time monitoring of biological parameters.
Read more on Tech Gist Africa: